Medscape is available in 5 Language Editions – Choose your Edition here.


Colon Cancer

  • Author: Tomislav Dragovich, MD, PhD; Chief Editor: N Joseph Espat, MD, MS, FACS  more...
Updated: May 07, 2016

Practice Essentials

Colon cancer is the most common type of gastrointestinal cancer. It is a multifactorial disease process, with etiology encompassing genetic factors, environmental exposures (including diet), and inflammatory conditions of the digestive tract.

Surgery currently is the definitive treatment modality.[1] The image below depicts standard colectomies for adenocarcinoma of the colon.

Standard colectomies for adenocarcinoma of the col Standard colectomies for adenocarcinoma of the colon.

See Cutaneous Clues to Diagnosing Metastatic Cancer, a Critical Images slideshow, to help identify various skin lesions that are cause for concern.

Signs and symptoms

Colon cancer is now often detected during screening procedures. Other common clinical presentations include the following:

  • Iron-deficiency anemia
  • Rectal bleeding
  • Abdominal pain
  • Change in bowel habits
  • Intestinal obstruction or perforation

Physical findings may include the following:

  • Early disease: Nonspecific findings (fatigue, weight loss) or none at all
  • More advanced disease: Abdominal tenderness, macroscopic rectal bleeding, palpable abdominal mass, hepatomegaly, ascites

See Clinical Presentation for more detail.


Laboratory studies that may be helpful include the following:

  • Complete blood count
  • Chemistries and liver function tests
  • Serum carcinoembryonic antigen

Imaging studies that may facilitate staging include the following:

  • Chest radiography
  • Chest computed tomography
  • Abdominal barium study
  • Abdominal/pelvic CT
  • Contrast ultrasonography of the abdomen and liver
  • Abdominal/pelvic MRI
  • Positron emission tomography, including fusion PET-CT scan

Other procedures that may be warranted include the following:

  • Colonoscopy
  • Sigmoidoscopy
  • Biopsy of suspicious lesions
  • Double-contrast barium enema

Current TNM classification is as follows:

  • Tx – No description of tumor extent possible, because of incomplete information
  • Tis – In situ carcinoma; tumor involves only muscularis mucosa
  • T1 – Cancer has grown through muscularis mucosa and extends into submucosa
  • T2 – Cancer has grown through submucosa and extends into muscularis propria
  • T3 – Cancer has grown through muscularis propria and into outermost layers of colon but not through them; it has not reached any nearby organs or tissues
  • T4a – Cancer has grown through serosa (visceral peritoneum)
  • T4b – Cancer has grown through wall of colon and is attached to or invades nearby tissues or organs
  • Nx – No description of lymph node involvement possible, because of incomplete information
  • N0 – No cancer in nearby lymph nodes
  • N1a – Cancer cells found in 1 nearby lymph node
  • N1b – Cancer cells found in 2-3 nearby lymph nodes
  • N1c – Small deposits of cancer cells found in areas of fat near lymph nodes, but not in lymph nodes themselves
  • N2a – Cancer cells found in 4-6 nearby lymph nodes
  • N2b – Cancer cells found in 7 or more nearby lymph nodes
  • M0 – No distant spread seen
  • M1a – Cancer has spread to 1 distant organ or set of distant lymph nodes
  • M1b – Cancer has spread to more than 1 distant organ or set of distant lymph nodes, or has spread to distant parts of the peritoneum

Staging is as follows:

Table 1. TNM Staging System for Colon Cancer (Open Table in a new window)

Stage Primary Tumor (T) Regional Lymph Node (N) Remote Metastasis (M)
Stage 0 Carcinoma in situ (Tis) N0 M0
Stage I Tumor may invade submucosa (T1) or muscularis propria (T2) N0 M0
Stage II Tumor invades muscularis (T3) or adjacent organs or structures (T4) N0 M0
Stage IIA T3 N0 M0
Stage IIB T4a N0 M0
Stage IIC T4b N0 M0
Stage IIIA T1-4 N1-2 M0
Stage IIIB T1-4 N1-2 M0
Stage IIIC T3-4 N1-2 M0
Stage IVA T1-4 N1-3 M1a
Stage IVB T1-4 N1-3 M1b

See Workup for more detail.


Surgery is the only curative modality for localized colon cancer (stage I-III). Surgical resection potentially provides the only curative option for patients with limited metastatic disease in liver and/or lung (stage IV disease). Surgical options include the following:

  • Right hemicolectomy: For lesions in the cecum and right colon
  • Extended right hemicolectomy: For lesions in the proximal or middle transverse colon
  • Left hemicolectomy: For lesions in the splenic flexure and left colon
  • Sigmoid colectomy: For sigmoid colon lesions
  • Total abdominal colectomy with ileorectal anastomosis: For selected patients with hereditary nonpolyposis colon cancer, attenuated familial adenomatous polyposis, metachronous cancers in separate colon segments, or acute malignant colon obstructions with unknown status of the proximal bowel

Other therapeutic options for patients who are not surgical candidates include the following:

  • Cryotherapy
  • Radiofrequency ablation
  • Hepatic arterial infusion of chemotherapeutic agents

Regimens used for systemic chemotherapy may include the following:

  • 5-Fluorouracil (5-FU)
  • Capecitabine
  • Tegafur
  • Oxaliplatin
  • Irinotecan
  • Combinations of multiple agents (eg, capecitabine or 5-FU with oxaliplatin, 5-FU with leucovorin and oxaliplatin)

Regimens used for adjuvant (postoperative) chemotherapy commonly include 5-FU with leucovorin or capecitabine, either alone or in combination with oxaliplatin.[2, 3, 4]

Biologic agents employed to treat colon cancer include the following:

  • Bevacizumab (Avastin)
  • Cetuximab (Erbitux)
  • Panitumumab (Vectibix)
  • Ramucirumab (Cyramza)
  • Regorafenib (Stivarga)
  • Ziv-aflibercept (Zaltrap)

See Treatment and Medication for more detail.



Invasive colorectal cancer is a preventable disease. Early detection through widely applied screening programs is the most important factor in the recent decline of colorectal cancer in developed countries (see Deterrence/Prevention).

Full implementation of screening guidelines[5] could cut mortality rate from colorectal cancer in the United States by an estimated additional 50%; even greater reductions are estimated for countries where screening tests may not be widely available at present. New and more comprehensive screening strategies are also needed.

Fundamental advances in understanding the biology and genetics of colorectal cancer are taking place. This knowledge is slowly making its way into the clinic and being employed to better stratify individual risks of developing colorectal cancer, discover better screening methodologies, allow for better prognostication, and improve the ability to predict benefit from new anticancer therapies.

In the past 10 years, an unprecedented advance in systemic therapy for colorectal cancer has dramatically improved outcome for patients with metastatic disease. Until the mid-1990s, the only approved agent for colorectal cancer was 5-fluorouracil. Since then, new agents in a variety of classes have become available, including the following:

  • Cytotoxic agents (eg, irinotecan, oxaliplatin) [6]
  • Oral fluoropyrimidines (ie, capecitabine and tegafur)
  • Biologic agents (eg, bevacizumab, cetuximab, panitumumab) [7]
  • Most recently, anti-angiogenic agents (ie, ziv-aflibercept, regorafenib)

Although surgery remains the definitive treatment modality, these new agents will likely translate into improved cure rates for patients with early-stage disease (stage II and III) and prolonged survival for those with stage IV disease. Further advances are likely to come from the development of new targeted agents and from better integration of systemic therapy with other modalities such as surgery, radiation therapy, and liver-directed therapies.

An image depicting standard colectomies for adenocarcinoma of the colon can be seen below.

Standard colectomies for adenocarcinoma of the col Standard colectomies for adenocarcinoma of the colon.

For more information, see Colorectal Cancer Guidelines.



Genetically, colorectal cancer represents a complex disease, and genetic alterations are often associated with progression from premalignant lesion (adenoma) to invasive adenocarcinoma. Sequence of molecular and genetic events leading to transformation from adenomatous polyps to overt malignancy has been characterized by Vogelstein and Fearon.[8]

The early event is a mutation of APC (adenomatous polyposis gene), which was first discovered in individuals with familial adenomatous polyposis (FAP). The protein encoded by APC is important in the activation of oncogene c-myc and cyclin D1, which drives the progression to malignant phenotype. Although FAP is a rare hereditary syndrome accounting for only about 1% of cases of colon cancer, APC mutations are very frequent in sporadic colorectal cancers.

In addition to mutations, epigenetic events such as abnormal DNA methylation can also cause silencing of tumor suppressor genes or activation of oncogenes. These events compromise the genetic balance and ultimately lead to malignant transformation.

Other important genes in colon carcinogenesis include the KRAS oncogene, chromosome 18 loss of heterozygosity (LOH) leading to inactivation of SMAD4 (DPC4), and DCC (deleted in colon cancer) tumor suppression genes. Chromosome arm 17p deletion and mutations affecting the p53 tumor suppressor gene confer resistance to programmed cell death (apoptosis) and are thought to be late events in colon carcinogenesis.

A subset of colorectal cancers is characterized with deficient DNA mismatch repair. This phenotype has been linked to mutations of genes such as MSH2, MLH1, and PMS2. These mutations result in so-called high frequency microsatellite instability (H-MSI), which can be detected with an immunocytochemistry assay. H-MSI is a hallmark of hereditary nonpolyposis colon cancer syndrome (HNPCC, Lynch syndrome), which accounts for about 6% of all colon cancers. H-MSI is also found in about 20% of sporadic colon cancers.



Colorectal cancer is a multifactorial disease process. Genetic factors, environmental exposures (including diet), and inflammatory conditions of digestive tract are all involved in the development of colorectal cancer.

Although much about colorectal cancer genetics remains unknown, current research indicates that genetic factors have the greatest correlation to colorectal cancer. Hereditary mutation of the APC gene is the cause of familial adenomatous polyposis (FAP), in which affected individuals carry an almost 100% risk of developing colon cancer by age 40 years.

Hereditary nonpolyposis colon cancer syndrome (HNPCC, Lynch syndrome) poses about a 40% lifetime risk for developing colorectal cancer; individuals with this syndrome are also at increased risk for urothelial cancer, endometrial cancer, and other less common cancers. Lynch syndrome is characterized by deficient mismatch repair (dMMR) due to inherited mutation in one of the mismatch repair genes, such as hMLH1, hMSH2, hMSH6, hPMS1, hPMS2, and possibly other undiscovered genes.

HNPCC is a cause of about 6% of all colon cancers. Although the use of aspirin may reduce the risk of colorectal neoplasia in some populations, a study by Burn et al found no effect on the incidence of colorectal cancer in carriers of Lynch syndrome with use of aspirin, resistant starch, or both.[9]

Dietary factors are the subject of intense and ongoing investigations.[10] Epidemiologic studies have linked increased risk of colorectal cancer with a diet high in red meat and animal fat, low-fiber diets, and low overall intake of fruits and vegetables. A study by Aune et al found that a high intake of fiber was associated with a reduced risk of colorectal cancer. In particular, cereal fiber and whole grains were found to be effective.[11] A study by Pala et al found that high yogurt intake was also associated with a decreased risk for colorectal cancer.[12]

Factors associated with lower risk include folate intake, calcium intake, and estrogen replacement therapy. However, most of these studies were retrospective epidemiologic studies and have yet to be validated in prospective, placebo-controlled, interventional trials.

Obesity and lifestyle choices such as cigarette smoking, alcohol consumption, and sedentary habits have also been associated with increased risk for colorectal cancer. A meta-analysis of prospective cohort studies found a modest but significant elevation of colorectal cancer risk in current smokers; risk was higher for men and for rectal cancers than colon cancers, and persisting in former smokers.[13]

In a large prospective study, Cho and colleagues reported that high alcohol consumption was associated with elevated risk for colorectal cancer, in individuals with a family history of the disease. The association was significant only for the highest alcohol intake category of 30 g or more daily; no significant linear trend was evident. In comparison with nondrinkers with no family history, individuals who consumed 30 g/d or more and who had a family history of colorectal cancer had a relative risk for colon cancer of 2.80.[14]

Current screening guidelines recommend that clinicians be aware of increased colorectal cancer risk in patients who smoke or are obese, but do not highlight the increased risk in patients with diabetes. A meta-analysis of case-control and cohort studies identified diabetes as an independent risk factor for colon and rectal cancer. Subgroup analyses confirmed the consistency of the findings across study type and population. This information may have an impact on screening guidelines and on building risk models of colorectal cancer.[15]

Association between body mass index (BMI) and risk of colorectal adenomas and cancer has been reported, but few studies have had adequate sample size for conducting stratified analyses. Jacobs et al pooled data from 8,213 participants in seven prospective studies and found that BMI was significantly related to most histologic characteristics of metachronous adenomas in men but not in women. The researchers concluded that body size may affect colorectal carcinogenesis at comparatively early stages, particularly in men.[16]

Activation of the WNT signaling pathway, which most often results from APC loss, plays a critical role in the development of colorectal cancer, and CTNNB1 (β-catenin) is a major mediator of the WNT pathway. WNT-CTNNB1 signaling also appears to be involved in obesity, glucose metabolism, and metabolic diseases such as obesity and type II diabetes. Consequently, Morikawa et al hypothesized that the association of obesity and physical activity with colorectal cancer risk might differ by tumor subtypes according to CTNNB1 status.[17]

Using a molecular pathological epidemiology database, these researchers determined that risk of CTNNB1-negative cancer was significantly higher with greater BMI and lower with increased physical activity level. These researchers found no association between either BMI or physical activity level and CTNNB1-positive cancer risk.[17]

Inflammatory bowel diseases such as ulcerative colitis and Crohn disease also carry an increased risk of developing colorectal adenocarcinoma. The risk for developing colorectal malignancy increases with the duration of inflammatory bowel disease and the greater extent of colon involvement.



Although the incidence and mortality from colon cancer have been on a slow decline over the past 20 years in the United States, colorectal cancers remain the third most common cancer and the third most common cause of cancer-related mortality in the US. The American Cancer Society estimates that 95,270 new cases of colon cancer will be diagnosed in the United States in 2016. Estimates for mortality from colon and rectal cancer (the two are combined because of classification difficulties) are for 49,190 deaths in 2016.[18]

Worldwide, colorectal cancer is the second most common in cancer in women (614,000 cases, 9.2% of all cancers) and the third most common in men (746,000 cases, 10.0% of the total). Geographically, the incidence varies as much as 10-fold. The highest estimated rates are in Australia/New Zealand (per 100,000 population, 44.8 in men and 32.2 in women), and the lowest in Western Africa (per 100,000 population, 4.5 in men and 3.8 in women).[19]

Mortality is lower (694,000 deaths, 8.5% of the total) with more deaths (52%) in the less-developed regions of the world, reflecting a poorer survival in these regions. There is less variability in mortality rates worldwide (six-fold in men, four-fold in women), with the highest estimated mortality rates in both sexes in Central and Eastern Europe (20.3 per 100,000 for men, 11.7 per 100,000 for women), and the lowest in Western Africa (3.5 and 3.0, respectively).

Racial, sexual, and age-related disparities in incidence

Recent trends in the United States suggest a disproportionally higher incidence and death from colon cancer in African Americans than in whites. Hispanics have the lowest incidence and mortality from colorectal cancer.

The incidence of colorectal cancer is relatively equal in men than in women. The American Cancer Society estimates that colon cancer will be diagnosed in 47,710 men and 47,560 women in the United States in 2016.[18]

Age is a well-known risk factor for colorectal cancer, as it is for many other solid tumors. The timeline for progression from early premalignant lesion to malignant cancer ranges from 10-20 years. Median age at diagnosis is 68 years.[20]



The approximate 5-year survival rate for colorectal cancer patients in the United States (all stages included) is 65%.[20] Survival is inversely related to stage: approximate 5-year survival rates are 95% for patients with stage I disease, 60% for those with stage III disease, and 10% for those with stage IV (metastatic) disease (see Staging).

A study by Chua et al found that approximately one in every three patients who undergo resection for colorectal liver metastases become actual 5-year survivors.[21] Of those, approximately half survive 10 years and are cured of colorectal liver metastases. A multivariate analysis of 1001 patients who underwent potentially curative resection of liver metastases identified five factors as independent predictors of worse outcome[22] :

  • Size greater than 5 cm
  • Disease-free interval of less than a year
  • More than one tumor
  • Primary lymph-node positivity
  • Carcinoembryonic antigen (CEA) level greater than 200 ng/mL

Aggarwal et al found that circulating tumor cells measured at baseline after the initiation of new therapy in patients with metastatic colorectal cancer independently predicted survival; in patients with a baseline carcinoembryonic antigen (CEA) value of 25 ng/mL or higher, those with low baseline levels of circulating tumor cells (< 3) had longer survival. Both the number of circulating tumor cells and the CEA level measured at 6-12 weeks independently predicted survival.[23]

Research suggests a role for intra-tumoral immune response as a predictor of clinical outcome in patients with colorectal cancer, in addition to more traditional pathological and molecular markers. Katz et al reported that in patients with colorectal liver metastases, high numbers of T regulatory cells relative to CD4 or CD8 T cells predicted poor outcome[24]

A study by Yothers et al found that black patients with resected stage II and stage III colon cancer had worse overall and recurrence-free survival compared with white patients who underwent the same therapy. Five-year overall survival rate was 68.2% for blacks and 72.8% for whites; the three-year recurrence-free survival was 68.4% in blacks and 72.1% in whites.[25]

A study by Campbell et al found that prediagnosis body mass index (BMI) is an important predictor of survival among patients with nonmetastatic colorectal cancer, whereas postdiagnosis BMI is not.[26] A separate study from Campbell et al found that spending 6 or more hours per day sitting was associated with higher all-cause mortality compared with sitting less than 3 hours per day. The study concluded that increased recreational physical activity in patients with colorectal carcinoma reduces mortality.[27]

A review of eight trials by Rothwell et al found that allocation to aspirin reduced death caused by cancer. Benefit was apparent after 5 years of follow-up. The 20-year risk of cancer death was also lower in the aspirin group for all solid cancers. A latent period of 5 years was observed before risk of death was decreased for esophageal, pancreatic, brain, and lung cancers. A more delayed latent period was observed for stomach, colorectal, and prostate cancer. The overall effect on 20-year risk of cancer death was greatest for adenocarcinomas.[28]

A study by Burn et al found that 600 mg of aspirin per day for a mean of 25 months reduced cancer incidence after 55.7 months among known carriers of hereditary colorectal cancer. However, further studies are needed to determine the optimum dose and duration of treatment.[29]

Patients with preexisting mental disorders have an overall higher mortality rate than their counterparts. This higher mortality rate can be attributed to a lack of surgery, chemotherapy, and radiation therapy, especially in patients with psychotic disorders and dementia. Improved public health initiatives are needed to improve colon cancer detection and treatment in older adults with mental disorders.[30]

A study by Phipps et al found that smoking is also associated with increased mortality after colorectal cancer diagnosis, especially in patients whose cancer has high microsatellite instability.[31] A study by Dehal et al found that patients with colorectal cancer and type 2 diabetes mellitus have a higher risk of mortality than those without, most notably a higher risk due to cardiovascular disease.[32]

Contributor Information and Disclosures

Tomislav Dragovich, MD, PhD Chief, Section of Hematology and Oncology, Banner MD Anderson Cancer Center

Tomislav Dragovich, MD, PhD is a member of the following medical societies: American Association for Cancer Research, SWOG, American Society of Clinical Oncology

Disclosure: Nothing to disclose.


Vassiliki L Tsikitis, MD Associate Professor of Surgery, Department of Surgery, Division of General and Gastrointestinal Surgery, Oregon Health and Science University School of Medicine

Vassiliki L Tsikitis, MD is a member of the following medical societies: American College of Surgeons, American Society of Colon and Rectal Surgeons, Association for Academic Surgery, Society for Surgery of the Alimentary Tract, SWOG, Association of Women Surgeons, Pacific Coast Surgical Association

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Chief Editor

N Joseph Espat, MD, MS, FACS Harold J Wanebo Professor of Surgery, Assistant Dean of Clinical Affairs, Boston University School of Medicine; Chairman, Department of Surgery, Director, Adele R Decof Cancer Center, Roger Williams Medical Center

N Joseph Espat, MD, MS, FACS is a member of the following medical societies: Alpha Omega Alpha, American Association for Cancer Research, American College of Surgeons, American Medical Association, American Society for Parenteral and Enteral Nutrition, American Society of Clinical Oncology, Americas Hepato-Pancreato-Biliary Association, Association for Academic Surgery, Central Surgical Association, Chicago Medical Society, International Hepato-Pancreato-Biliary Association, Pancreas Club, Sigma Xi, Society for Leukocyte Biology, Society for Surgery of the Alimentary Tract, Society of American Gastrointestinal and Endoscopic Surgeons, Society of Surgical Oncology, Society of University Surgeons, Southeastern Surgical Congress, Southern Medical Association, Surgical Infection Society

Disclosure: Nothing to disclose.

Additional Contributors

Philip Schulman, MD Chief, Medical Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center

Philip Schulman, MD is a member of the following medical societies: American Association for Cancer Research, American College of Physicians, American Society of Hematology, Medical Society of the State of New York

Disclosure: Nothing to disclose.

  1. PDQ Adult Treatment Editorial Board. Colon Cancer Treatment–Health Professional Version. National Cancer Institute. Available at January 29, 2016; Accessed: April 14, 2016.

  2. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004 Jan 1. 22(1):23-30. [Medline].

  3. Haller DG, Catalano PJ, Macdonald JS, O'Rourke MA, Frontiera MS, Jackson DV. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol. 2005 Dec 1. 23(34):8671-8. [Medline].

  4. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004 Jun 3. 350(23):2335-42. [Medline].

  5. [Guideline] Desch CE, Benson AB 3rd, Somerfield MR, et al. Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2005 Nov 20. 23(33):8512-9. [Medline].

  6. Sanoff HK, Sargent DJ, Campbell ME, et al. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol. 2008 Dec 10. 26(35):5721-7. [Medline].

  7. Chu, E and DeVita VT. Physicians’ cancer chemotherapy drug manual. Jones and Bartlett publishers. 2008.

  8. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988 Sep 1. 319(9):525-32. [Medline].

  9. Burn J, Bishop DT, Mecklin JP, Macrae F, et al. Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med. 2008 Dec 11. 359(24):2567-78. [Medline].

  10. Meyerhardt JA, Niedzwiecki D, Hollis D, et al. Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. JAMA. 2007 Aug 15. 298(7):754-64. [Medline].

  11. Aune D, Chan DS, Lau R, et al. Dietary fibre, whole grains, and risk of colorectal cancer: systematic review and dose-response meta-analysis of prospective studies. BMJ. 2011 Nov 10. 343:d6617. [Medline]. [Full Text].

  12. Pala V, Sieri S, Berrino F, et al. Yogurt consumption and risk of colorectal cancer in the Italian European prospective investigation into cancer and nutrition cohort. Int J Cancer. 2011 Dec 1. 129(11):2712-9. [Medline].

  13. Tsoi KK, Pau CY, Wu WK, Chan FK, Griffiths S, Sung JJ. Cigarette smoking and the risk of colorectal cancer: a meta-analysis of prospective cohort studies. Clin Gastroenterol Hepatol. 2009 Jun. 7(6):682-688.e1-5. [Medline].

  14. Cho E, Lee JE, Rimm EB, Fuchs CS, Giovannucci EL. Alcohol consumption and the risk of colon cancer by family history of colorectal cancer. Am J Clin Nutr. 2012 Feb. 95(2):413-9. [Medline]. [Full Text].

  15. Yuhara H, Steinmaus C, Cohen SE, Corley DA, Tei Y, Buffler PA. Is diabetes mellitus an independent risk factor for colon cancer and rectal cancer?. Am J Gastroenterol. 2011 Nov. 106(11):1911-21; quiz 1922. [Medline].

  16. Jacobs ET, Ahnen DJ, Ashbeck EL, Baron JA, Greenberg ER, Lance P, et al. Association between body mass index and colorectal neoplasia at follow-up colonoscopy: a pooling study. Am J Epidemiol. 2009 Mar 15. 169(6):657-66. [Medline].

  17. Morikawa T, Kuchiba A, Lochhead P, et al. Prospective Analysis of Body Mass Index, Physical Activity, and Colorectal Cancer Risk Associated with ß-Catenin (CTNNB1) Status. Cancer Res. 2013 Mar 1. 73(5):1600-10. [Medline]. [Full Text].

  18. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014 Jan-Feb. 64(1):9-29. [Medline].

  19. World Health Organization, International Agency for Research on Cancer. Colorectal Cancer: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. International Agency for Research on Cancer. Available at Accessed: January 27, 2016.

  20. Surveillance, Epidemiology, and End Results Program. SEER Stat Fact Sheets: Colon and Rectum Cancer. National Cancer Institute. Available at Accessed: January 27, 2016.

  21. Chua TC, Saxena A, Chu F, Zhao J, Morris DL. Predictors of cure after hepatic resection of colorectal liver metastases: an analysis of actual 5- and 10-year survivors. J Surg Oncol. 2011 Jun. 103(8):796-800. [Medline].

  22. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep. 230(3):309-18; discussion 318-21. [Medline].

  23. Aggarwal C, Meropol NJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, et al. Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer. Ann Oncol. 2012 Oct 1. [Medline].

  24. Katz SC, Bamboat ZM, Maker AV, Shia J, Pillarisetty VG, Yopp AC, et al. Regulatory T Cell Infiltration Predicts Outcome Following Resection of Colorectal Cancer Liver Metastases. Ann Surg Oncol. 2012 Sep 26. [Medline].

  25. Yothers G, Sargent DJ, Wolmark N, et al. Outcomes Among Black Patients With Stage II and III Colon Cancer Receiving Chemotherapy: An Analysis of ACCENT Adjuvant Trials. J Natl Cancer Inst. 2011 Oct 19. 103(20):1498-1506. [Medline]. [Full Text].

  26. Campbell PT, Newton CC, Dehal AN, et al. Impact of body mass index on survival after colorectal cancer diagnosis: the Cancer Prevention Study-II Nutrition Cohort. J Clin Oncol. 2012 Jan 1. 30(1):42-52. [Medline].

  27. Campbell PT, Patel AV, Newton CC, Jacobs EJ, Gapstur SM. Associations of recreational physical activity and leisure time spent sitting with colorectal cancer survival. J Clin Oncol. 2013 Mar 1. 31(7):876-85. [Medline].

  28. Rothwell PM, Fowkes GR, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomized trials. Lancet. Dec 7/2010; Early online publication. [Full Text].

  29. Burn J, Gerdes AM, Macrae F, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet. 2011 Dec 17. 378(9809):2081-7. [Medline]. [Full Text].

  30. Baillargeon J, Kuo YF, Lin YL, et al. Effect of mental disorders on diagnosis, treatment, and survival of older adults with colon cancer. J Am Geriatr Soc. 2011 Jul. 59(7):1268-73. [Medline].

  31. Phipps AI, Baron J, Newcomb PA. Prediagnostic smoking history, alcohol consumption, and colorectal cancer survival: The Seattle Colon Cancer Family Registry. Cancer. 2011 Nov 1. 117(21):4948-57. [Medline]. [Full Text].

  32. Dehal AN, Newton CC, Jacobs EJ, et al. Impact of diabetes mellitus and insulin use on survival after colorectal cancer diagnosis: the Cancer Prevention Study-II Nutrition Cohort. J Clin Oncol. 2012 Jan 1. 30(1):53-9. [Medline].

  33. American Cancer Society. Cancer Facts & Figures 2016. American Cancer Society. Available at Accessed: January 27, 2016.

  34. Rex DK, Johnson DA, Anderson JC, Schoenfeld PS, Burke CA, Inadomi JM. American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. Am J Gastroenterol. 2009 Mar. 104(3):739-50. [Medline]. [Full Text].

  35. Mulcahy N. Test all colorectal cancers for Lynch syndrome. NCCN: Medscape Medical News. Available at Accessed: March 14, 2014.

  36. Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Rüschoff J, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004 Feb 18. 96(4):261-8. [Medline]. [Full Text].

  37. Thirunavukarasu P, Sukumar S, Sathaiah M, Mahan M, Pragatheeshwar KD, Pingpank JF, et al. C-stage in Colon Cancer: Implications of Carcinoembryonic Antigen Biomarker in Staging, Prognosis, and Management. J Natl Cancer Inst. 2011 Apr 20. 103(8):689-97. [Medline].

  38. Littlejohn C, Hilton S, Macfarlane GJ, Phull P. Systematic review and meta-analysis of the evidence for flexible sigmoidoscopy as a screening method for the prevention of colorectal cancer. Br J Surg. 2012 Sep 21. [Medline].

  39. Wilschut JA, Habbema JD, van Leerdam ME, et al. Fecal occult blood testing when colonoscopy capacity is limited. J Natl Cancer Inst. 2011 Dec 7. 103(23):1741-51. [Medline].

  40. Jensen CD, Corley DA, Quinn VP, Doubeni CA, Zauber AG, Lee JK, et al. Fecal Immunochemical Test Program Performance Over 4 Rounds of Annual Screening: A Retrospective Cohort Study. Ann Intern Med. 2016 Jan 26. [Medline]. [Full Text].

  41. Douglas D. Clopidogrel Boosts Bleeding Risk After Polypectomy. Available at Accessed: April 24, 2013.

  42. Gandhi S, Narula N, Mosleh W, Marshall JK, Farkouh M. Meta-analysis: colonoscopic post-polypectomy bleeding in patients on continued clopidogrel therapy. Aliment Pharmacol Ther. 2013 May. 37(10):947-52. [Medline].

  43. Nelson R. FDA Approves Cologuard for Colorectal Cancer Screening. Medscape Medical News. Available at Accessed: August 16, 2014.

  44. Brooks M. FDA Clears First Blood-Based Colorectal Cancer Screening Test. Medscape Medical News. Available at April 14, 2016; Accessed: April 14, 2016.

  45. [Guideline] Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin. 2008 May-Jun. 58(3):130-60. [Medline].

  46. Lasser KE, Murillo J, Lisboa S, et al. Colorectal cancer screening among ethnically diverse, low-income patients: a randomized controlled trial. Arch Intern Med. 2011 May 23. 171(10):906-12. [Medline].

  47. Spada C, De Vincentis F, Cesaro P, Hassan C, Riccioni ME, Minelli Grazioli L, et al. Accuracy and safety of second-generation PillCam COLON capsule for colorectal polyp detection. Therap Adv Gastroenterol. 2012 May. 5(3):173-8. [Medline]. [Full Text].

  48. Lieberman DA, Rex DK, Winawer SJ, Giardiello FM, Johnson DA, Levin TR. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2012 Sep. 143(3):844-57. [Medline]. [Full Text].

  49. [Guideline] American Society for Clinical Pathology, the College of American Pathologists, the Association for Molecular Pathology, and the American Society of Clinical Oncology. Guideline on the Evaluation of Molecular Markersfor Colorectal Cancer Expert Panel Draft Recommendations Summary for Open Comment Period. Available at Accessed: May 13, 2015.

  50. Nelson R. New guidelines on colorectal cancer molecular testing. Medscape Medical News. Available at Accessed: May 13, 2015.

  51. Greene FL, Page DL, Fleming ID, et al. Cancer staging manual. 6th ed. New York: Springer; 2002.

  52. Ogino S, Kawasaki T, Kirkner GJ, Ohnishi M, Fuchs CS. 18q loss of heterozygosity in microsatellite stable colorectal cancer is correlated with CpG island methylator phenotype-negative (CIMP-0) and inversely with CIMP-low and CIMP-high. BMC Cancer. 2007 May 2. 7:72. [Medline].

  53. Jimeno A, Messersmith WA, Hirsch FR, Franklin WA, Eckhardt SG. KRAS Mutations and Sensitivity to Epidermal Growth Factor Receptor Inhibitors in Colorectal Cancer: Practical Application of Patient Selection. J Clin Oncol. 2009 Jan 5. [Medline].

  54. Quasar Collaborative Group, Gray R, Barnwell J, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007 Dec 15. 370(9604):2020-9. [Medline].

  55. Saltz LB, Kelsen DP. Adjuvant treatment of colorectal cancer. Annu Rev Med. 1997. 48:191-202. [Medline].

  56. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003 Jul 17. 349(3):247-57. [Medline].

  57. Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol. 2011 Feb 20. 29(6):610-8. [Medline].

  58. Le Voyer TE, Sigurdson ER, Hanlon AL, et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol. 2003 Aug 1. 21(15):2912-9. [Medline].

  59. Gunderson LL, Jessup JM, Sargent DJ, Greene FL, Stewart AK. Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010 Jan 10. 28(2):264-71. [Medline]. [Full Text].

  60. Hugen N, van de Velde CJ, de Wilt JH, Nagtegaal ID. Metastatic pattern in colorectal cancer is strongly influenced by histological subtype. Ann Oncol. 2014 Mar. 25(3):651-7. [Medline].

  61. Boggs W. Histology influences colorectal cancer metastatic pattern. Reuters Health Information. March 11, 2014. [Full Text].

  62. Boller AM, Nelson H. Colon and rectal cancer: laparoscopic or open?. Clin Cancer Res. 2007 Nov 15. 13(22 Pt 2):6894s-6s. [Medline].

  63. Fleshman J, Sargent DJ, Green E, Anvari M, Stryker SJ, Beart RW Jr. Laparoscopic colectomy for cancer is not inferior to open surgery based on 5-year data from the COST Study Group trial. Ann Surg. 2007 Oct. 246(4):655-62; discussion 662-4. [Medline].

  64. Jayne DG, Guillou PJ, Thorpe H, et al. Randomized trial of laparoscopic-assisted resection of colorectal carcinoma: 3-year results of the UK MRC CLASICC Trial Group. J Clin Oncol. 2007 Jul 20. 25(21):3061-8. [Medline].

  65. Kuhry E, Schwenk WF, Gaupset R, Romild U, Bonjer HJ. Long-term results of laparoscopic colorectal cancer resection. Cochrane Database Syst Rev. 2008 Apr 16. CD003432. [Medline].

  66. Lacy AM, Delgado S, Castells A, et al. The long-term results of a randomized clinical trial of laparoscopy-assisted versus open surgery for colon cancer. Ann Surg. 2008 Jul. 248(1):1-7. [Medline].

  67. Veldkamp R, Kuhry E, Hop WC, et al. Laparoscopic surgery versus open surgery for colon cancer: short-term outcomes of a randomised trial. Lancet Oncol. 2005 Jul. 6(7):477-84. [Medline].

  68. Poultsides GA, Servais EL, Saltz LB, Patil S, Kemeny NE, Guillem JG. Outcome of Primary Tumor in Patients With Synchronous Stage IV Colorectal Cancer Receiving Combination Chemotherapy Without Surgery As Initial Treatment. J Clin Oncol. 2009 Jun 1. [Medline].

  69. Nitzkorski JR, Farma JM, Watson JC, Siripurapu V, Zhu F, Matteotti RS, et al. Outcome and natural history of patients with stage IV colorectal cancer receiving chemotherapy without primary tumor resection. Ann Surg Oncol. 2012 Feb. 19(2):379-83. [Medline].

  70. Venderbosch S, de Wilt JH, Teerenstra S, et al. Prognostic value of resection of primary tumor in patients with stage IV colorectal cancer: retrospective analysis of two randomized studies and a review of the literature. Ann Surg Oncol. 2011 Nov. 18(12):3252-60. [Medline]. [Full Text].

  71. Di Benedetto F, Berretta M, D'Amico G, et al. Liver resection for colorectal metastases in older adults: a paired matched analysis. J Am Geriatr Soc. 2011 Dec. 59(12):2282-90. [Medline].

  72. Brouquet A, Overman MJ, Kopetz S, et al. Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified?. Cancer. 2011 Oct 1. 117(19):4484-92. [Medline]. [Full Text].

  73. House MG, Kemeny NE, Gonen M, et al. Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer. Ann Surg. 2011 Dec. 254(6):851-6. [Medline].

  74. van Hooft JE, Bemelman WA, Oldenburg B, et al. Colonic stenting versus emergency surgery for acute left-sided malignant colonic obstruction: a multicentre randomised trial. Lancet Oncol. 2011 Apr. 12(4):344-52. [Medline].

  75. Saunders R. Adjuvant Chemo May Benefit Elderly Colon Cancer Patients. Medscape Medical News. Available at Accessed: September 13, 2013.

  76. van Erning FN, Creemers GJ, De Hingh IH, Loosveld OJ, Goey SH, Lemmens VE. Reduced risk of distant recurrence after adjuvant chemotherapy in patients with stage III colon cancer aged 75 years or older. Ann Oncol. 2013 Aug 8. [Medline].

  77. Sargent D, Sobrero A, Grothey A, O'Connell MJ, Buyse M, Andre T, et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2009 Feb 20. 27(6):872-7. [Medline].

  78. Benson AB 3rd, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004 Aug 15. 22(16):3408-19. [Medline].

  79. O'Connor ES, Greenblatt DY, LoConte NK, et al. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol. 2011 Sep 1. 29(25):3381-8. [Medline]. [Full Text].

  80. Kim GP, Sargent DJ, Mahoney MR, Rowland KM Jr, Philip PA, Mitchell E, et al. Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841. J Clin Oncol. 2009 Jun 10. 27(17):2848-54. [Medline]. [Full Text].

  81. Seymour MT, Thompson LC, Wasan HS, et al. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet. 2011 May 21. 377(9779):1749-59. [Medline].

  82. Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015 May 14. 372 (20):1909-19. [Medline].

  83. Bennouna J, Sastre J, Arnold D, Osterlund P, Greil R, Van Cutsem E, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2013 Jan. 14(1):29-37. [Medline].

  84. Kabbinavar FF, Hurwitz HI, Yi J, Sarkar S, Rosen O. Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. J Clin Oncol. 2009 Jan 10. 27(2):199-205. [Medline].

  85. Koopman M, Simkens L, May A, Mol L, van Tinteren H, Punt CJA, et al. Final results and subgroup analyses of the phase 3 CAIRO3 study: Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC). (abstract LBA388). Presented at: 2014 Gastrointestinal Cancers Symposium (GICS); January 18, 2014; San Francisco, Calif. J Clin Oncol. 2014. 32 (suppl 3):abstr LBA388. [Full Text].

  86. Nelson R. Maintenance chemo delays progression in metastatic CRC. Medscape Medical News. January 27, 2014. [Full Text].

  87. Tebbutt NC, Murphy F, Zannino D, et al. Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab. Ann Oncol. 2011 Aug. 22(8):1834-8. [Medline].

  88. Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Petrelli NJ, Colangelo LH, et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol. 2011 Jan 1. 29(1):11-6. [Medline].

  89. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004 Jul 22. 351(4):337-45. [Medline].

  90. Van Cutsem E, Köhne CH, Láng I, Folprecht G, Nowacki MP, Cascinu S, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011 May 20. 29(15):2011-9. [Medline].

  91. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009 Apr 2. 360(14):1408-17. [Medline]. [Full Text].

  92. Lin AY, Buckley NS, Lu AT, et al. Effect of KRAS mutational status in advanced colorectal cancer on the outcomes of anti-epidermal growth factor receptor monoclonal antibody therapy: a systematic review and meta-analysis. Clin Colorectal Cancer. 2011 Mar 1. 10(1):63-9. [Medline].

  93. Chustecka Z. FDA Approves Panitumumab for Use With FOLFOX in mCRC. Medscape Medical News. Available at Accessed: June 2, 2014.

  94. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010 Nov 1. 28(31):4697-705. [Medline].

  95. Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol. 2010 Nov 1. 28(31):4706-13. [Medline].

  96. Price TJ, Peeters M, Kim TW, Li J, Cascinu S, Ruff P, et al. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol. 2014 May. 15(6):569-79. [Medline].

  97. Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol. 2009 Feb 10. 27(5):672-80. [Medline].

  98. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009 Feb 10. 27(5):663-71. [Medline].

  99. Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013 Sep 12. 369(11):1023-34. [Medline].

  100. Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 2015 Apr 10. [Medline].

  101. Stivarga (regorafenib) [package insert]. Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc. September 2012. Available at [Full Text].

  102. Grothey A, Sobrero AF, Salvatore S, Falcone A, Ychou M, Heinz-Josef L, et al. Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients with metastatic colorectal cancer (mCRC) who have progressed after standard therapies. J Clin Oncol 30, 2012 (suppl 4; abstr LBA385). [Full Text].

  103. Patel A, Sun W. Ziv-aflibercept in metastatic colorectal cancer. Biologics. 2014. 8:13-25. [Medline]. [Full Text].

  104. Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausová J, Macarulla T, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012 Oct 1. 30(28):3499-506. [Medline].

  105. Hendlisz A, Van den Eynde M, Peeters M, Maleux G, Lambert B, Vannoote J, et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol. 2010 Aug 10. 28(23):3687-94. [Medline].

  106. Harrison P. HER2 Therapy in Advanced Colorectal Cancer: 'Extraordinary'. Medscape Medical News. Available at May 3, 2016; Accessed: May 7, 2016.

  107. Sartore-Bianchi A, Trusolino L, Martino C, Bencardino K, Lonardi S, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016 Apr 20. [Medline]. [Full Text].

  108. [Guideline] Meyerhardt JA, Mangu PB, Flynn PJ, Korde L, Loprinzi CL, Minsky BD, et al. Follow-Up Care, Surveillance Protocol, and Secondary Prevention Measures for Survivors of Colorectal Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement. J Clin Oncol. 2013 Nov 12. [Medline].

  109. [Guideline] Labianca R, Nordlinger B, Beretta GD, Mosconi S, Mandalà M, Cervantes A, et al. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013 Oct. 24 Suppl 6:vi64-72. [Medline].

  110. [Guideline] National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Colon Cancer Version 2.2016. Available at Accessed: April 14, 2016.

  111. Chustecka Z. Guidelines for Follow-up of Colorectal Cancer Patients. Medscape Medical News. Available at Accessed: November 18, 2013.

  112. Kirkegaard H, Johnsen NF, Christensen J, Frederiksen K, Overvad K, Tjonneland A. Association of adherence to lifestyle recommendations and risk of colorectal cancer: a prospective Danish cohort study. BMJ. 2010 Oct 26. 341:c5504. [Medline]. [Full Text].

  113. Meyerhardt JA, Heseltine D, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, et al. Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol. 2006 Aug 1. 24(22):3535-41. [Medline].

  114. Morikawa T, Kuchiba A, Yamauchi M, et al. Association of CTNNB1 (beta-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer. JAMA. 2011 Apr 27. 305(16):1685-94. [Medline]. [Full Text].

  115. Arber N, Spicak J, Rácz I, Zavoral M, Breazna A, Gerletti P, et al. Five-year analysis of the prevention of colorectal sporadic adenomatous polyps trial. Am J Gastroenterol. 2011 Jun. 106(6):1135-46. [Medline].

  116. Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet. 2007 May 12. 369(9573):1603-13. [Medline].

  117. Cole BF, Logan RF, Halabi S, Benamouzig R, Sandler RS, Grainge MJ, et al. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst. 2009 Feb 18. 101(4):256-66. [Medline].

  118. Zhang X, Smith-Warner SA, Chan AT, et al. Aspirin Use, Body Mass Index, Physical Activity, Plasma C-Peptide, and Colon Cancer Risk in US Health Professionals. Am J Epidemiol. 2011 Aug 15. 174(4):459-67. [Medline].

  119. Nishihara R, Lochhead P, Kuchiba A, Jung S, Yamauchi M, Liao X, et al. Aspirin use and risk of colorectal cancer according to BRAF mutation status. JAMA. 2013 Jun 26. 309(24):2563-71. [Medline].

  120. Cook NR, Lee IM, Zhang SM, Moorthy MV, Buring JE. Alternate-Day, Low-Dose Aspirin and Cancer Risk: Long-Term Observational Follow-up of a Randomized Trial. Ann Intern Med. 2013 Jul 16. 159(2):77-85. [Medline].

  121. Meyskens FL Jr, McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter PM, Hawk E, et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila Pa). 2008 Jun. 1(1):32-8. [Medline].

  122. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004 Jan 15. 22(2):229-37. [Medline].

  123. Arkenau HT, Arnold D, Cassidy J, Diaz-Rubio E, Douillard JY, Hochster H, et al. Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials. J Clin Oncol. 2008 Dec 20. 26(36):5910-7. [Medline].

  124. Sehgal R, Lembersky BC, Rajasenan KK, et al. A Phase I/II Study of Capecitabine Given on a Week on/Week off Schedule Combined With Bevacizumab and Oxaliplatin for Patients With Untreated Advanced Colorectal Cancer. Clin Colorectal Cancer. 2011 Jun. 10(2):117-20. [Medline].

  125. Chustecka Z. Stop using calcium and magnesium with oxaliplatin. Medscape Medical News. June 3, 2013. [Full Text].

  126. Chustecka Z. Bevacizumab’s indication extended in colorectal cancer. Medscape Medical News. Jan 24, 2013. Available at Accessed: January 27, 2016.

  127. Corley DA, Jensen CD, Marks AR, Zhao WK, Lee JK, Doubeni CA, et al. Adenoma detection rate and risk of colorectal cancer and death. N Engl J Med. 2014 Apr 3. 370(14):1298-306. [Medline].

  128. Given Imaging Receives FDA Clearance for PillCam® COLON in Patients Following Incomplete Colonoscopy. Given Imaging. Available at Accessed: January 27, 2016.

  129. Laidman J. Colonoscopy May Reduce Late-Stage Colon Cancer Risk by 70%. Available at Accessed: January 27, 2016.

Standard colectomies for adenocarcinoma of the colon.
Table 1. TNM Staging System for Colon Cancer
Stage Primary Tumor (T) Regional Lymph Node (N) Remote Metastasis (M)
Stage 0 Carcinoma in situ (Tis) N0 M0
Stage I Tumor may invade submucosa (T1) or muscularis propria (T2) N0 M0
Stage II Tumor invades muscularis (T3) or adjacent organs or structures (T4) N0 M0
Stage IIA T3 N0 M0
Stage IIB T4a N0 M0
Stage IIC T4b N0 M0
Stage IIIA T1-4 N1-2 M0
Stage IIIB T1-4 N1-2 M0
Stage IIIC T3-4 N1-2 M0
Stage IVA T1-4 N1-3 M1a
Stage IVB T1-4 N1-3 M1b
Table 1. TNM Staging System for Colon Cancer
Stage Primary Tumor (T) Regional Lymph Node (N) Remote Metastasis (M)
Stage 0 Carcinoma in situ (Tis) N0 M0
Stage I Tumor may invade submucosa (T1) or muscularis propria (T2) N0 M0
Stage II Tumor invades muscularis (T3) or adjacent organs or structures (T4) N0 M0
Stage IIA T3 N0 M0
Stage IIB T4a N0 M0
Stage IIC T4b N0 M0
Stage IIIA T1-4 N1-2 M0
Stage IIIB T1-4 N1-2 M0
Stage IIIC T3-4 N1-2 M0
Stage IVA T1-4 N1-3 M1a
Stage IVB T1-4 N1-3 M1b
Table 2. Surveillance recommendations for stage II and III colon cancer
Parameter Organization
ESMO [JSMO](2013) ASCO (2013) NCCN (2016)
History and physical exam Every 3-6 mo for 3 y, then every 6 -12 mo at 4 and 5 y Every 3-6 mo for 3 y, then every 6 mo to 5 y Every 3-6 mo for 2 y, then every 6 mo to 5 y
CEA Every 3-6 mo for 3 y, then every 6 -12 mo at 4 and 5 y Every 3 mo for 3 y* Every 3-6 mo for 2 y, then every 6 mo to 5 y
Chest CT* Every 6-12 mo for first 3 y Every 1 y for 3 y Every 1 y for 5 y
Colonoscopy** At y 1 after surgery, and every 3-5 y thereafter At 1 y, then every 5 y, dictated by the findings on the previous colonoscopy At 1 y, 3 y, then every 5 y if negative
Abdominal CT* Every 6-12 mo for first 3 y Every 1 y for 3 y Every 6-12 mo for up to 5 y; scans to include chest and pelvis
ESMO = European Society of Medical Oncology; JSMO = Japanese Society of Medical Oncology; ASCO = American Society of Clinical Oncology; NCCN = National Comprehensive Cancer Network; CEA = carcinoembryonic antigen; CT = computed tomography

* For patients at high risk for recurrence (eg, lymphatic or venous invasion, or poorly differentiated tumors).

**Colonoscopy should be performed 3-6 mo postoperatively if preoperative colonoscopy was not done, due to an obstructing lesion; otherwise, colonoscopy in 1 y; if abnormal, repeat in 1 year; if no advanced adenoma (ie, villous polyp, polyp > 1 cm, or high-grade dysplasia), repeat in 3 y, then every 5 y.

All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.